


# BMJ Open SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based cohort study

Joel G Ray ,<sup>1,2</sup> Alison L Park<sup>2</sup>

**To cite:** Ray JG, Park AL. SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based cohort study. *BMJ Open* 2022;**12**:e059944. doi:10.1136/bmjopen-2021-059944

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-059944>).

Received 07 December 2021  
Accepted 30 June 2022

## ABSTRACT

**Objective** To compare outcomes between O and non-O blood groups, and by modified RNA (mRNA) and adenovirus-vectored (Ad-V) vaccines.

**Design** Population-based cohort study.

**Setting** All of Ontario, Canada. Linked data sets captured clinical encounters, vaccinations and laboratory testing for SARS-CoV-2.

**Participants** Individuals aged 12+ years with known ABO blood group and free of SARS-CoV-2 before 15 January 2021.

**Main outcomes measures** The main exposure, first SARS-CoV-2 vaccination, was modelled in a time-varying manner. O and non-O blood group was known prior to vaccination. SARS-CoV-2 infection, and severe COVID-19 (hospitalisation or death), were assessed starting 14 days after vaccination, up to 27 June 2021.

**Results** 2 472 261 individuals were included. 1 743 916 (70.5%) had at least one vaccination, of which 24.6% were fully vaccinated. Those vaccinated were more likely to be women, older in age, residing in a higher-income area and have higher rates of certain comorbid conditions, like cancer, diabetes and hypertension. Relative to unvaccinated, after receiving their first mRNA (adjusted HR (aHR) 0.46, 95% CI 0.44 to 0.47) or Ad-V (aHR 0.49, 95% CI 0.44 to 0.54) vaccine, the risk of SARS-CoV-2 infection was lower, as was severe COVID-19 (aHR 0.29, 95% CI 0.20 to 0.43 (mRNA); aHR 0.29, 95% CI 0.26 to 0.33 (Ad-V)). Stratifying by blood group produced similar results. For example, after first mRNA vaccination, the aHR of severe COVID-19 was 0.31 (95% CI 0.27 to 0.36) among non-O blood groups, and 0.27 (95% CI 0.22 to 0.32) among O blood groups, relative to unvaccinated. Fully vaccinated individuals had the lowest risk of SARS-CoV-2 and severe COVID-19.

**Conclusions** SARS-CoV-2 infection and severe COVID-19 are reduced by vaccination. This effect does not vary by vaccine type or blood group, but is more pronounced among fully, than partially, vaccinated individuals.

## INTRODUCTION

Emergence of the SARS-CoV-2 pandemic, and COVID-19-related disease, led to rapid development of various vaccines. Efficacy was demonstrated for the modified RNA (mRNA) vaccine of the SARS-CoV-2 spike protein, to induce neutralising antibodies,<sup>1</sup> as well as a recombinant, replication-incompetent

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This study was limited to persons who had ABO blood group testing, and who are more likely to have required blood transfusion or to have been pregnant in the past.
- ⇒ We did not know who had acquired natural immunity to SARS-CoV-2.
- ⇒ The potential for immortal time bias was mitigated by treating vaccine exposure as time varying, and by setting follow-up time to a common starting date.
- ⇒ The current study was largely completed prior to the emergence of the SARS-CoV-2 Delta/B.1.617 variant.

adenovirus vector that encodes a full-length and stabilised SARS-CoV-2 spike protein (adenovirus-vectored (Ad-V)).<sup>2</sup> Demonstrated vaccine efficacy shown from pooled data of randomised clinical trials is 95% (95% CI 94 to 95) and 80% (95% CI 56 to 93), respectively.<sup>3</sup> Even within 14 days of receipt of a first dose, vaccine efficacy can reach 80%.<sup>4,5</sup>

It is of interest that adults with O blood group appear to be at lower risk of SARS-CoV-2 infection and COVID-19-related severe illness, compared with those with A, B and AB (ie, non-O) blood groups.<sup>6,7</sup> Those with O blood group are identified by their anti-A and anti-B antibodies; these same antibodies may offer immunoprotection against SARS-CoV-2, as they are concomitantly produced by certain epithelial cells within the respiratory and digestive tract—prime targets for COVID-19 tissue injury.<sup>7</sup> What is not known, however, is whether vaccinated persons with O blood group experience different rates of SARS-CoV-2 infection and COVID-19 disease than those of non-O blood group. Such information might guide vaccine type, recipient prioritisation and the need for repeat vaccination.

The current study evaluated SARS-CoV-2 infection and COVID-19 disease in a population with a universal vaccination system offered to those aged 12+ years, a high



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Medicine, St. Michael's Hospital, Toronto, Ontario, Canada

<sup>2</sup>ICES, Toronto, Ontario, Canada

## Correspondence to

Dr Joel G Ray; [RayJ@smh.ca](mailto:RayJ@smh.ca)



uptake of at least one vaccine<sup>8</sup> and systematic collection of vaccination and infection data. Herein, we compared outcomes between O and non-O blood groups, and by mRNA and Ad-V vaccines.

## METHOD

This population-based retrospective cohort study was performed in Ontario, Canada. Patient-level data sets included all hospitalisations, emergency department visits, the majority of laboratory tests for SARS-CoV-2 and all SARS-CoV-2 vaccinations administered within Ontario,<sup>9</sup> as further detailed in online supplemental table S1.<sup>6,10</sup> Data sets were linked using unique encoded identifiers and analysed at ICES.

Study eligibility required that an individual was aged 12+ years, a resident of Ontario, had undergone ABO testing and also did not have an SARS-CoV-2 positive swab before 15 January 2021 (online supplemental table S1 and figure S1).

## Exposures and outcomes

The main study exposure was a first SARS-CoV-2 vaccination, handled in a time-varying manner, with a lag of 14 days after vaccination to ensure that the person had a chance to develop immunity. High-risk persons were first vaccinated on 15 December 2020, and Canada started mass vaccinating its citizens on 15 January 2021.<sup>11</sup> So, for example, a person who was vaccinated on 1 January 2021 or earlier was considered exposed on 15 January 2021, whereas a person who was vaccinated on 1 February 2021 was considered exposed on 15 February 2021 and unexposed before that date.

The main study outcome was *SARS-CoV-2 infection*, defined as a positive SARS-CoV-2 PCR test—regardless of indication, symptoms or illness severity—arising during the follow-up period, from 15 January 2021 to 27 June 2021. The second study outcome was a *severe COVID-19*, defined as a positive SARS-CoV-2 PCR test in conjunction with either a hospitalisation within  $\pm 3$  days, or a death within  $-1$  to  $+3$  days, of that positive PCR test. A  $\pm 3$ -day margin was to allow for PCR testing antecedent to, or following, the hospital admission. The  $-1$  day window permitted the possibility that a PCR specimen was labelled on the day following a COVID-19 death. Both study outcomes were assessed starting at least 14 days after vaccination, among those vaccinated<sup>12</sup> (online supplemental table S1).

## Data analyses

For the overall cohort, study outcomes were based on population-at-risk denominators, which included both those who did and did not necessarily undergo SARS-CoV-2 PCR testing after 15 January 2021. Time-to-event analyses generated incidence rates, and Cox proportional hazard models produced unadjusted and adjusted HRs, comparing first-vaccinated to unvaccinated persons (referent). Censoring occurred if a person lost their Ontario Health Insurance Plan coverage, were

outcome-free by 27 June 2021 (the end of study period), or the day after they died (if a death occurred). HRs were adjusted for age, sex, rural residence, area income quintile—each at baseline—as well as prior diabetes mellitus, malignancy, heart failure, cardiac ischaemia or arrhythmia, chronic kidney disease or venous thromboembolism (online supplemental table S1). Additional analysis 1, (online supplemental table S2) restricted the at-risk denominator for those individuals who underwent SARS-CoV-2 PCR testing at least 14 days after their first vaccination.

The main cohort model was repeated, with each study outcome assessed by more specifically comparing first mRNA vaccination or first Ad-V vaccination to unvaccinated persons (referent).

Next, and central to the study, we examined the risk of each study outcome in relation to first-vaccination status, further stratified by O and non-O blood groups. This was done among the entire cohort, as well as restricted to those who underwent SARS-CoV-2 PCR testing at least 14 days after their first vaccination.

Consideration was given to receipt of a second vaccination as a time-dependent variable. Hence, ‘fully vaccinated’ and ‘partially vaccinated’ persons were each compared with unvaccinated individuals, stratified by O and non-O groups—with these analyses conducted among the whole cohort, as well as limited to just those who had SARS-CoV-2 testing in the observation period.

Analyses were planned a priori. Statistical analyses were performed using SAS V.9.4 for UNIX (SAS Institute, Cary, North Carolina, USA).

## Patient and public involvement

No patient was consulted or involved in this study.

- ▶ Did we involve patients/service users/carers/lay people in the design of this study? No.
- ▶ Was the development of outcome measures informed by patients’ priorities, experience and preferences? No.
- ▶ Were patients/carers/lay people involved in the recruitment to and conduct of the study? No.
- ▶ How will the results be disseminated to study participants? Not applicable.
- ▶ Are patients/carers/lay people thanked in the contributorship statement/acknowledgements? Not applicable.
- ▶ Was the development of the research question and outcome measures informed by patients’ priorities, experience and preferences? No.

## RESULTS

Among 2 938 215 individuals, 2 472 261 met the inclusion criteria (online supplemental figure S1). Of these, 1 743 916 (70.5%) had at least one vaccination (table 1). Those vaccinated were more likely to be women, older in age, residing in a higher-income area and have higher rates of certain comorbid conditions, like cancer, diabetes and hypertension (table 1). Of those vaccinated, 1 600 524

**Table 1** Characteristics of 2 472 261 individuals in Ontario, Canada, aged 12 years and older, with known ABO blood group and without evidence of SARS-CoV-2 infection before 15 January 2021. All data are presented as a number (%) unless otherwise indicated

Characteristic		Any SARS-CoV-2 vaccination (N=1 743 916)	No SARS-CoV-2 vaccination (N=728 345)	Standardised difference
<b>On 15 January 2021 (time zero)</b>				
Mean (SD) age, year		50.8 (18.4)	40.6 (15.4)	0.60
12–17		13 009 (0.7)	11 509 (1.6)	0.08
18–39		589 158 (33.8)	415 983 (57.1)	0.48
40–59		568 693 (32.6)	208 310 (28.6)	0.09
60–69		218 653 (12.5)	42 386 (5.8)	0.23
70–79		209 118 (12.0)	29 116 (4.0)	0.30
80+		145 285 (8.3)	21 041 (2.9)	0.24
Female		1 200 499 (68.8)	548 647 (75.3)	0.15
Area income quintile (Q)*	Q1 (lowest)	298 360 (17.1)	182 483 (25.1)	0.20
	Q2	332 128 (19.0)	153 526 (21.1)	0.05
	Q3	360 666 (20.7)	147 174 (20.2)	0.01
	Q4	375 199 (21.5)	134 421 (18.5)	0.08
	Q5 (highest)	373 655 (21.4)	108 469 (14.9)	0.17
Rural residence†	Rural	164 607 (9.4)	76 733 (10.5)	0.04
Pregnant		23 137 (1.3)	19 410 (2.7)	0.10
O blood group		315 903 (43.4)	751 212 (43.1)	0.01
<b>Pre-existing conditions</b>				
Diabetes mellitus		292 661 (16.8)	70 062 (9.6)	0.21
Malignancy		405 034 (23.2)	104 741 (14.4)	0.23
Heart failure		89 604 (5.1)	18 085 (2.5)	0.14
Cardiac ischaemia or arrhythmia		144 692 (8.3)	27 106 (3.7)	0.19
Chronic kidney disease		90 732 (5.2)	19 760 (2.7)	0.13
Venous thromboembolism		41 006 (2.4)	13 342 (1.8)	0.04
Stroke or transient ischaemic attack		31 638 (1.8)	6763 (0.9)	0.08
Chronic hypertension		571 167 (32.8)	116 201 (16.0)	0.40
Asthma		300 546 (17.2)	126 172 (17.3)	0.00
Dementia, or frailty		264 694 (15.2)	107 972 (14.8)	0.01
Anaemia		265 861 (15.2)	96 060 (13.2)	0.06
Chronic obstructive pulmonary disease		89 413 (5.1)	20 352 (2.8)	0.12
HIV or organ transplant		9754 (0.6)	2770 (0.4)	0.03
<b>At time of first vaccination</b>				
Vaccine type	Modified RNA	1 600 524 (91.8)	--	--
	Adenovirus-vectored	143 358 (8.2)	--	--
	Unspecified	34 (0.0)	--	--
Vaccine name	AstraZeneca	117 100 (6.7)	--	--
	Covishield	26 086 (1.5)	--	--
	Janssen	172 (0.0)	--	--
	Moderna	315 370 (18.1)	--	--
	Pfizer	1 285 154 (73.7)	--	--
	Unspecified	34 (0.0)	--	--
	<b>At the time of second vaccination</b>			

Continued

**Table 1** Continued

Characteristic		Any SARS-CoV-2 vaccination (N=1 743 916)	No SARS-CoV-2 vaccination (N=728 345)	Standardised difference
Vaccine type	<i>Modified RNA</i>	415 632 (23.8)	--	--
	<i>Adenovirus-vectored</i>	12 855 (0.7)	--	--
	<i>Unspecified</i>	16 (0.0)	--	--
	<i>No second dose</i>	1 315 413 (75.4)	--	--
Vaccine name	<i>AstraZeneca</i>	12 692 (0.7)	--	--
	<i>Covishield</i>	157 (0.0)	--	--
	<i>Janssen</i>	6 (0.0)	--	--
	<i>Moderna</i>	86 791 (5.0)	--	--
	<i>Pfizer</i>	328 841 (18.9)	--	--
	<i>Unspecified</i>	16 (0.0)	--	--
	<i>No second dose</i>	1 315 413 (75.4)	--	--
	Received two vaccine doses by 13 June 2021 (14 days prior to end of follow-up)	428 503 (24.6)	--	--
Vaccine dose 2 same as dose 1	<i>Same</i>	424 517 (24.3)	--	--
	<i>Different</i>	3969 (0.2)	--	--
	<i>Unknown</i>	17 (0.0)	--	--
	<i>No second dose</i>	1 315 413 (75.4)	--	--
Median (IQR) follow-up for assessing the primary study outcome, d	163.0 (163.0–163.0)	163.0 (163.0–163.0)	0.39	
Median (IQR) follow-up for assessing the secondary study outcome, d	163.0 (163.0–163.0)	163.0 (163.0–163.0)	0.16	
Had SARS-CoV-2 PCR testing during follow-up period, from 15 January 2021 onward	439 058 (25.2)	175 397 (24.1)	0.03	
*Missing for 6180 (0.25%) of all persons. †Missing for 5247 (0.21%) of all persons. ‡Before 15 January 2021.				

(91.8%) first received an mRNA vaccine, and 143 358 (8.2%) an Ad-V vaccine. A second vaccine was administered to 24.6% of individuals by 13 June 2021 (ie, by 2 weeks before the end of the study observation period), comprising the mRNA vaccine among 415 632 (23.8%) and the Ad-V among 12 855 (0.7%) (table 1).

After a median follow-up of 163 days (IQR 163–163), the rate of SARS-CoV-2 positivity was 0.54 per 10 000 person-days among first-vaccinated persons, and 1.69 per 10 000 person-days among non-vaccinated persons—an unadjusted HR of 0.38 (95% CI 0.37 to 0.39) and an adjusted HR of 0.46 (95% CI 0.45 to 0.48). The corresponding HR were equally protective for those receiving a first mRNA vaccine (adjusted HR 0.46, 95% CI 0.44 to 0.47) or first Ad-V vaccine (adjusted HR 0.49, 95% CI 0.44 to 0.54), each relative to being unvaccinated (table 2). The adjusted HR for severe COVID-19 was 0.29 (95% CI 0.26 to 0.33) comparing vaccinated to unvaccinated persons, with similar estimates by vaccine type (table 2).

There were 439 058 (25.2%) vaccinated people who had SARS-CoV-2 PCR testing during follow-up period, from 15 January 2021 onward, compared with 175 397 (24.1%) unvaccinated individuals—a small standardised difference of 0.03. Restricting the at-risk denominator to 614 455 individuals, and comparing the vaccinated to the unvaccinated, the adjusted HR were 0.28 (95% CI 0.27 to 0.29) for SARS-CoV-2 positivity, and 0.22 (95% CI 0.20 to 0.25) for severe COVID-19, although, at much higher event rates than seen in the entire cohort (Additional analysis 1, online supplemental table S2).

Among the entire cohort, the protective effect associated with a first mRNA or Ad-V vaccine against SARS-CoV-2 infection or severe COVID-19 was equally seen among those with O and non-O blood groups (figure 1, upper). This pattern was also seen by vaccine type (online supplemental table S3), and among the 614 455 individuals who had SARS-CoV-2 PCR testing (figure 1, lower).

In the entire cohort, relative to the unvaccinated, fully vaccinated individuals had the lowest risk of SARS-CoV-2



**Table 2** SARS-CoV-2 vaccination and associated risk of SARS-CoV-2 infection, or severe COVID-19 (hospitalisation or death)—each assessed starting at least 14 days after the first vaccination, among the entire cohort. Data are presented by time-varying exposure after first vaccination versus unvaccinated (upper blue), as well as by first-vaccination type versus unvaccinated (lower maroon)

Study outcome	Exposure state*	No. person-days of follow-up*	No. with outcome (rate per 10 000 person-days)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)†
SARS-CoV-2 infection	Unvaccinated (N=2 464 998)	303 209 192	51 187 (1.69)	1.00 (referent)	1.00 (referent)
	Vaccinated (N=1 743 916)	93 324 805	4995 (0.54)	0.38 (0.37 to 0.39)	0.46 (0.45 to 0.48)
Severe COVID-19‡	Unvaccinated (N=2 464 998)	307 438 194	2890 (0.09)	1.00 (referent)	1.00 (referent)
	Vaccinated (N=1 743 916)	93 575 031	491 (0.05)	0.71 (0.64 to 0.79)	0.29 (0.26 to 0.33)
SARS-CoV-2 infection	Unvaccinated (N=2 464 998)	303 209 192	51 187 (1.69)	1.00 (referent)	1.00 (referent)
	Adenovirus-vectored (N=143 358)	8 263 735	434 (0.53)	0.39 (0.36 to 0.43)	0.49 (0.44 to 0.54)
	Modified RNA (N=1 600 524)	85 059 246	4561 (0.54)	0.38 (0.37 to 0.39)	0.46 (0.44 to 0.47)
Severe COVID-19	Unvaccinated (N=2 464 998)	307 438 194	2890 (0.09)	1.00 (referent)	1.00 (referent)
	Adenovirus-vectored (N=143 358)	8 284 162	27 (0.03)	0.46 (0.31 to 0.68)	0.29 (0.20 to 0.43)
	Modified RNA (N=1 600 524)	85 289 045	464 (0.05)	0.73 (0.66 to 0.82)	0.29 (0.26 to 0.33)

\*Exposure is time-varying, therefore, some individuals may have contributed time as unvaccinated, and then subsequently, as vaccinated.

†Adjusted for age, sex, rural residence, area income quintile—each at baseline—as well as prior diabetes mellitus, malignancy, heart failure, cardiac ischaemia or arrhythmia, chronic kidney disease or venous thromboembolism.

‡In the vaccinated and unvaccinated groups, respectively, there were 21 deaths (0.02 per 100 000 person-days) and 133 deaths (0.04 per 100 000 person-days), from 1 day before, up to 3 days after, an SARS-CoV-2 positive PCR test, with a corresponding adjusted HR of 0.24 (95% CI 0.14 to 0.41).

infection, followed by partially vaccinated persons (figure 2, upper). For example, among those with blood group O, the corresponding adjusted HR were 0.39 (95% CI 0.34 to 0.43) and 0.48 (95% CI 0.45 to 0.50). Moreover, the HRs did not differ by blood group. The same was evident for severe COVID-19 (figure 2, upper). Restricting to the subcohort who had SARS-CoV-2 testing, the protective effect conferred by full and partial vaccination was similar by blood groups (figure 2, lower).

## DISCUSSION

### Main findings

This population-based cohort study observed a lower risk of SARS-CoV-2 infection, as well as severe COVID-19 hospitalisation or death, in association with SARS-CoV-2 vaccination. This conferred protective effect did not vary by vaccine type or blood group, but was more pronounced among fully, than partially, vaccinated individuals.

### Comparison with other studies


A 2021 meta-analysis of 54 218 persons showed a lower risk of SARS-CoV-2 infection comparing O versus non-O blood group (OR 0.71, 95% CI 0.60 to 0.84).<sup>13</sup> In a cohort study of 225 556 adults and children in Ontario, before SARS-CoV-2 vaccination, we previously observed a lower relative risk of SARS-CoV-2 infection (0.88, 95% CI 0.84 to 0.92) and severe COVID-19 illness or death (0.87, 95% CI 0.78 to 0.97) among those with O versus non-O blood group.<sup>6</sup> The current study is the first to explore effect modification of O blood group on vaccine effectiveness against SARS-CoV-2 infection or related illness. Just as we found no effect modification, prior research on the

smallpox vaccine suggested no differences in ‘vaccine success’ by ABO blood group,<sup>14</sup> nor for influenza A,<sup>15</sup> rabies<sup>16</sup> and cholera<sup>17</sup> vaccines. Thus, if O blood group is somehow protective against SARS-CoV-2 infection or illness, it is unlikely to generate any additive benefit to that conferred by available mRNA and Ad-V vaccines.


The current study observed a relative risk reduction against severe COVID-19 of between 82% and 85% after full vaccination, and between 67% and 70% following partial vaccination (figure 2). In Chile, among those aged 60+ years and fully vaccinated, vaccine effectiveness was 67% against infection, 85% for the prevention of hospitalisation and 87% for the prevention of COVID-19-related death, with corresponding estimates of 16%, 37% and 46% after partial vaccination.<sup>18</sup> Our findings about vaccine effectiveness are similar to those of randomised clinical trials of SARS-CoV-2 vaccination,<sup>1-4</sup> or another observational study from Ontario.<sup>10</sup> Taken together, SARS-CoV-2 vaccination by mRNA or Ad-V is effective at preventing serious disease.

### Limitations

This study was limited to persons who had ABO blood group testing, and who are more likely to have required blood transfusion or to have been pregnant in the past.<sup>6</sup> As a study strength, identification of blood group status preceded SARS-CoV-2 vaccination or index PCR testing. While we excluded those with SARS-CoV-2 infection prior to 15 January 2021, we did not know who had acquired natural immunity. While vaccination and study outcomes were fully ascertained within a universal healthcare system, a minority of individuals may have been vaccinated



**Figure 1** SARS-CoV-2 vaccination and associated risk of SARS-CoV-2 infection, or severe COVID-19 (hospitalisation or death), stratified by O and non-O blood groups. Data are presented for the entire cohort (upper panel), and 614 455 individuals who had SARS-CoV-2 PCR testing during the follow-up period (lower panel). Analyses are by time-varying exposure after first vaccination. Unadjusted HRs are in red, and adjusted HRs in blue, adjusted for age, sex, rural residence, area income quintile—each at baseline—as well as prior diabetes mellitus, malignancy, heart failure, cardiac ischaemia or arrhythmia, chronic kidney disease or venous thromboembolism.



**Figure 2** Full or partial SARS-CoV-2 vaccination and associated risk of SARS-CoV-2 infection, or severe COVID-19 (hospitalisation or death), stratified by O and non-O blood groups. Data are presented for the entire cohort (upper panel), and 614 455 individuals who had SARS-CoV-2 PCR testing during the follow-up period (lower panel). Analyses are by time-varying exposure after first vaccination. Unadjusted HRs are in red, and adjusted HRs in blue, adjusted for age, sex, rural residence, area income quintile—each at baseline—as well as prior diabetes mellitus, malignancy, heart failure, cardiac ischaemia or arrhythmia, chronic kidney disease or venous thromboembolism.



outside of Ontario and not identified herein. The potential for immortal time bias—the influence of misclassified follow-up time for individuals who were vaccinated, which could differentially favour their survival—was mitigated by treating vaccine exposure as time varying and by setting follow-up time to a common starting date of 15 January 2021.<sup>19</sup> All study covariates, including demographic and clinical variables, were captured prior to time zero. A protective effect of vaccination was seen in the additional analyses restricted to those who underwent PCR testing. This was akin to using a test-negative design, in which common access to, and uptake of, medical care can reduce unmeasured confounding related to healthcare-seeking behaviours.<sup>20</sup> While the current study was largely completed prior to the emergence of the SARS-CoV-2 Delta/B.1.617 variant, it is unlikely that ABO blood group would be expected to modify vaccine effectiveness within the subsequent period. Last, adverse events following immunisation were not studied herein, nor the tendency for such adverse events related to ABO blood group.

## CONCLUSIONS

The protective benefit offered by mRNA or Ad-V SARS-CoV-2 vaccination—especially full vaccination—is not further modulated by ABO blood group status. Large-scale population or targeted vaccination programmes should continue, with ongoing research about how to mitigate emerging viral variants.

**Contributors** JR and ALP: Study concept, analysis and interpretation of the data, drafting of manuscript, manuscript revision and approval of final version.

**Funding** Funded by a grant from the Ontario Academic Health Sciences Centre AFP Innovation Fund, and the Ontario Ministry of Health (MOH). This study was also supported by ICES, which is funded by an annual grant from the Ontario MOH and the Ministry of Long-Term Care. Parts of this material are based on data and information compiled and provided by MOH and the Canadian Institute for Health Information.

**Disclaimer** The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** The use of data in this project was authorised under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a Research Ethics Board.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** No data are available. No additional data available.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which

permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID ID

Joel G Ray <http://orcid.org/0000-0003-1635-4658>

## REFERENCES

- Polack FP, Thomas SJ, Kitchin N, *et al*. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020;383:2603–15.
- Sadoff J, Le Gars M, Shukarev G, *et al*. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. *N Engl J Med* 2021;384:1824–35.
- Pormohammad A, Zarei M, Ghorbani S, *et al*. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. *Vaccines* 2021;9:467.
- Baden LR, El Sahly HM, Essink B, *et al*. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* 2021;384:403–16.
- Thompson MG, Burgess JL, Naleway AL, *et al*. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:495–500.
- Ray JG, Schull MJ, Vermeulen MJ, *et al*. Association Between ABO and Rh Blood Groups and SARS-CoV-2 Infection or Severe COVID-19 Illness: A Population-Based Cohort Study. *Ann Intern Med* 2020:M20-4511.
- Goel R, Bloch EM, Pirenne F, *et al*. ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working group. *Vox Sang* 2021;116:849–61.
- ICES. ICES COVID-19 Dashboard, 2022. Available: <https://www.ices.on.ca/DAS/AHRQ/COVID-19-Dashboard#vaccinecoverage> [Accessed 16 May 2022].
- Ontario Ministry of Health. COVID-19 vaccine data in Ontario, 2022. Available: <https://data.ontario.ca/dataset/covid-19-vaccine-data-in-ontario> [Accessed 16 May 2022].
- Chung H, He S, Nasreen S, *et al*. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. *BMJ* 2021;374:n1943.
- Suissa S. Immortal time bias in pharmaco-epidemiology. *Am J Epidemiol* 2008;167:492–9.
- National Advisory Committee on immunization (NACI): statements and publications. recommendations on the use of COVID-19 vaccines, 2021. Available: <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html#t19> [Accessed 15 Aug 2021].
- Liu N, Zhang T, Ma L, *et al*. The impact of ABO blood group on COVID-19 infection risk and mortality: a systematic review and meta-analysis. *Blood Rev* 2021;48:100785.
- Bourke GJ, Clarke N, Thornton EH. Smallpox vaccination: ABO and rhesus blood groups. *J Med Genet* 1965;2:122–5.
- Mackenzie JS, Fimmel PJ. The effect of ABO blood groups on the incidence of epidemic influenza and on the response to live attenuated and detergent split influenza virus vaccines. *J Hyg* 1978;80:21–30.
- Buchta C, Körmöczy G, Heinze G, *et al*. Lack of impact of ABO blood group or corresponding isoantibodies on the immune response after rabies vaccination. *Wien Klin Wochenschr* 2005;117:412–6.
- Ramamurthy T, Wagener D, Chowdhury G, *et al*. A large study on immunological response to a whole-cell killed oral cholera vaccine reveals that there are significant geographical differences in response and that O blood group individuals do not elicit a higher response. *Clin Vaccine Immunol* 2010;17:1232–7.
- Jara A, Undurraga EA, González C, *et al*. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. *N Engl J Med* 2021;385:875–84.
- Calip GS, Miksad RA, Sarkar S. Time-Related biases in nonrandomized COVID-19-Era studies using real-world data. *JAMA Oncol* 2021. doi:10.1001/jamaoncol.2021.1715. [Epub ahead of print: 17 Jun 2021].
- Dean NE, Hogan JW, Schnitzer ME. Covid-19 vaccine effectiveness and the test-negative design. *N Engl J Med Overseas Ed* 2021;385:1431–3.



**Table S1. Variables used to define cohort entry and exclusion criteria, as well as study exposures, outcomes, adjustment, and stratification.**

Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
<i>Inclusion criteria</i>	ABO-Rh specimen date January 2007 to December 2020	Individuals with an ABO blood group test result in Ontario, Canada	--	LOINC codes 882-1, 883-9, 10331-7 in the Ontario Laboratory Information System ( <a href="#">OLIS</a> ) - includes most outpatient laboratory information in Ontario	--
<i>Exclusion criteria</i>	SARS-CoV-2 specimen date January 15, 2020 to January 14, 2021	Individuals with a SARS-CoV-2 RNA PCR positive laboratory result in Ontario, Canada prior to time zero	--	OLISC19 - includes Test Request (TR)/LOINC codes for SARS-CoV-2 and other respiratory virus testing: TR12936-1, TR12937-9, 94315-9, 94314-2, 94316-7, XON13512-9, XON13529-3, XON13528-5, XON13531-9, XON13527-7. These codes, plus keywords such as "COVID", "SARS-CoV-2", "Novel coronavirus" or "nCOV" or microorganism SNOMED codes (840533007 [SARS-CoV-2], 168209000 [No Virus Identified]), were used to define the data pull from OLIS.	For the ICES methodology and Python script for cleaning and parsing OLIS lab results for SARS-CoV-2 and other respiratory viruses, see <a href="https://github.com/icescentral/COVID19-Lab-Results">https://github.com/icescentral/COVID19-Lab-Results</a>
	January 15, 2021 (time zero)	Implausible or missing sex, birth date or death date	--	Registered Persons Database ( <a href="#">RPDB</a> ) - contains demographic information and encrypted healthcare numbers for all individuals eligible for OHIP	--
	Same as above	Non-Ontario resident or not eligible for OHIP at time zero	--	RPDB	--
	Same as above	Aged less < 12 years at time zero	--	RPDB	--

Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
	Same as above	Death occurred before baseline, before the vaccination date, or > 1 day before the SARS-CoV-2 specimen date	Discharge disposition is not alive ( <a href="#">DAD</a> , <a href="#">NACRS</a> )	RPDB, COVAXON, OLISC19	--
	December 15, 2020 to June 13, 2021	Duplicate vaccination record	--	COVAXON	--
<i>Study exposures</i>	December 15, 2020 to June 13, 2021	COVID-19 partially vaccinated status	--	COVAXON	--
	Same as above	COVID-19 1 <sup>st</sup> dose type (mRNA, viral vector, unknown, none)	--	COVAXON	--
	Same as above	COVID-19 fully-vaccinated status (fully-vaccinated, partially-vaccinated, unvaccinated)	--	COVAXON	--
<i>Stratification variable</i>	January 2007 to December 2020	ABO blood group (O, other)	--	LOINC codes 882-1, 883-9, 10331-7 in OLIS	--
<i>Main study outcome</i>	SARS-CoV-2 specimen date January 15, 2021 (time zero) to June 27, 2021, censored at loss OHIP eligibility or the day after death.	Earliest SARS-CoV-2 positive test.	--	OLISC19	--

Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
<i>Secondary study outcome</i>	SARS-CoV-2 specimen date January 15, 2021 (time zero) to June 30, 2021, censored at loss OHIP eligibility or the day after death.	Earliest SARS-CoV-2 positive test <u>AND</u> a hospital admission within +/- 3 days or death within -1 to +3 days of the SARS-CoV-2 specimen date.	DAD (hospital admission, not alive at discharge), NACRS (hospital admission, not alive at discharge), SDS (not alive at discharge)	OLISC19 (SARS-CoV-2 test), RPDB (death)	--
<i>Covariates</i>	January 15, 2021 (time zero)	Age	--	RPDB	--
	Same as above	Sex	--	RPDB	--
	Same as above	Area income quintile	--	Statistics Canada <a href="#">Census</a>	--
	Same as above	Rural residence	--	Statistics Canada <a href="#">Census</a>	--
	Any time before January 15, 2021 (time zero)	Diabetes mellitus	The ICES-derived <a href="#">ODD</a> database was used to identify patients with diagnosed diabetes before the index date, based on 2 OHIP diagnostic codes or 1 OHIP fee code or 1 DAD/SDS diagnostic code, within 2 years.  ICD-10-CA: E10, E11, E13, E14	OHIP ICD-9: 250 OHIP fee codes: Q040, K029, K030, K045, K046	<a href="https://pubmed.ncbi.nlm.nih.gov/11874939/">https://pubmed.ncbi.nlm.nih.gov/11874939/</a>

Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
	Same as above	History of heart failure	The ICES-derived <a href="#">CHF</a> database was used to identify patients with CHF, based on 1 ED, hospitalization or outpatient claim, and a second claim in 1 year. <i>The CHF database is limited to those 40 years of age or older.</i>  ICD-10-CA (DAD, SDS): I500, I501, I509	OHIP ICD-9: 428	<a href="https://pubmed.ncbi.nlm.nih.gov/23735455/">https://pubmed.ncbi.nlm.nih.gov/23735455/</a>
	Within 5 years before January 15, 2021 (time zero)	History of malignant neoplasm	ICD-10-CA (DAD, SDS, NACRS): C00-C97	--	--
	Same as above	Chronic kidney disease (CKD)	<u>CKD diagnosis</u> ICD-10-CA (DAD, NACRS): E102, E112, E132, E142, I12, I13, N08, N18, N19	<u>CKD diagnosis</u> ICD-9 (OHIP): 403, 585	<a href="https://pubmed.ncbi.nlm.nih.gov/23560464/">https://pubmed.ncbi.nlm.nih.gov/23560464/</a>



Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
			<u>Chronic dialysis</u> At least 2 of the following CCI (DAD, SDS) codes separated by 90 days, but < 150 days, in the year before the index date: 1PZ21	<u>Chronic dialysis</u> At least 2 of the following OHIP fee codes separated by 90 days, but < 150 days, in the year before the index date: R849, G082, G083, G085, G090-G096, G294, G295, G323, G325, G326, G330-G333, G860-G866, H540, H740  Treatment codes (CORR): 060, 111, 112, 113, 121, 122, 123, 131, 132, 133, 141, 151, 152, 211, 221, 231, 241, 242, 251, 252, 311, 312, 313, 321, 322, 323, 331, 332, 333, 413, 423, 433, 443, 453	<a href="https://pubmed.ncbi.nlm.nih.gov/20613656/">https://pubmed.ncbi.nlm.nih.gov/20613656/</a>
			<u>Exclude kidney transplant CCI (DAD): 1PC85</u>	<u>Exclude kidney transplant</u> OHIP fee codes: S435, S434  CORR treatment code: 171 plus $\geq 1$ Transplanted Organ Code [1-3]: 10, 11, 12, 18, 19	<a href="https://pubmed.ncbi.nlm.nih.gov/26019887/">https://pubmed.ncbi.nlm.nih.gov/26019887/</a>

Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
	Same as above	History of cardiac ischemia	<p>At least 1 hospitalization (DAD) or ED (NACRS) visit with a diagnosis or procedure coded with 1 of the following codes:</p> <p><u>Angina:</u> ICD-10-CA: I20, I2382, I24</p> <p><u>Chronic Ischemic Heart Disease:</u> ICD-10-CA: I25</p> <p><u>Myocardial infarction:</u> ICD-10-CA: I21, I22</p> <p><u>Coronary Artery Bypass Grafting:</u> CCI: 1I176, 1I180</p> <p><u>Percutaneous Coronary Intervention:</u> CCI: 1I126, 1I150, 1I155, 1I157</p>	--	<a href="https://pubmed.ncbi.nlm.nih.gov/20847972/">https://pubmed.ncbi.nlm.nih.gov/20847972/</a>

Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
	Same as above	History of cardiac arrhythmia	<p>At least 1 hospitalization (DAD) or ED (NACRS) visit with a diagnosis or procedure coded with 1 of the following codes:</p> <p><u>Atrial Fibrillation/Atrial Flutter:</u> ICD-10-CA: I48</p> <p><u>Ventricular Arrhythmia &amp; Tachycardia:</u> ICD-10-CA: I470, I472, I490, I493</p> <p><u>Permanent Pacemaker:</u> CCI: 1HZ53GRNM, 1HZ53LANM, 1HZ53GRNK, 1HZ53LANK, 1HZ53GRNL, 1HZ53LANL</p> <p><u>Implantable Cardioverter-Defibrillator:</u> CCI: 1HZ53GRFS, 1HZ53LAFS, 1HZ53SYFS, 1HZ53HAFS</p>	--	<p><a href="https://pubmed.ncbi.nlm.nih.gov/19433698/">https://pubmed.ncbi.nlm.nih.gov/19433698/</a></p> <p><a href="https://www.ices.on.ca/Publications/Atlases-and-Reports/2006/Canadian-Institute-for-Health-Information">https://www.ices.on.ca/Publications/Atlases-and-Reports/2006/Canadian-Institute-for-Health-Information</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/17599603/">https://pubmed.ncbi.nlm.nih.gov/17599603/</a></p>

Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
	Same as above	History of pulmonary embolism, deep vein thrombosis, or other venous thromboembolism	ICD-10-CA (DAD, SDS, NACRS): I260, I269, O88201, O88202, O88203, O88204, O88209, I636, I822, I828, I829, I801, I802, I803, I808, I809, O22301, O22303, O22309, O22501, O22503, O22509, O87102, O87104, O87109, O87304, O87309, I676, I81, I820, I823, O228, O229, O878, O879  <u>AND</u>  one of the following CCI codes for diagnostic imaging during the same admission: 3KX30DA, 3KX30DB, 3KX30DC, 3KX30DD, 3KR10VC, 3KR10VN, 3KR12VA, 3KX10VA, 3KX10VC, 3KX10VN, 3KX10VX, 3KX12VA, 3IM10VC, 3IM10VX, 3IM10VY, 3IM12VA, 3GT70CA, 3GT70CC, 3GT70CE, 3GT70KC, 3GT70KD, 3GT70KE, 3JY10VA, 3JY10VC, 3JY10VN, 3JY10VX, 3JY12VA, 3JY20WC	OHIP ICD-9: 677, 415, 671, 451, 452  <u>AND</u>  one of the following OHIP radiological professional fee codes for a VTE diagnostic test billed within 3 days: J198, J498, J193, J493, J202, J502, J206, J506, J182, J482, X406, X407, X125, X188, X401, X405, X408, X126, X410, X231, X232, X233, X127, X413, X421, X425, J659, J660, J859, J860	--



Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
<i>Other baseline variables</i>	Any time before January 15, 2021 (time zero)	Asthma	The ICES-derived <a href="#">ASTHMA</a> database was used to identify patients with diagnosed asthma before the index date, based on 2 OHIP diagnostic codes or 1 DAD diagnostic code.  ICD-10-CA: J45, J46	OHIP ICD-9: 493	<a href="https://pubmed.ncbi.nlm.nih.gov/20011725/">https://pubmed.ncbi.nlm.nih.gov/20011725/</a>
	Same as above	Chronic obstructive pulmonary disease (COPD)	The ICES-derived <a href="#">COPD</a> database was used to identify patients with diagnosed COPD before the index date, based on 1 OHIP diagnostic code or 1 DAD diagnostic code.  ICD-10-CA: J41-J44	OHIP ICD-9: 491, 492, 496	<a href="https://pubmed.ncbi.nlm.nih.gov/19863368/">https://pubmed.ncbi.nlm.nih.gov/19863368/</a> <i>The COPD algorithm was validated in those aged ≥ 35 years.</i>
	Same as above	Chronic hypertension	The ICES-derived <a href="#">HYPER</a> database was used to identify patients with: a) 1 hospital admission with a hypertension diagnosis, or b) an OHIP claim with a hypertension diagnosis followed within 2 years by either an OHIP claim or a hospital admission with a hypertension diagnosis.  ICD-10-CA (DAD, SDS): I10-I13, I15	OHIP ICD-9: 401-405	<a href="https://pubmed.ncbi.nlm.nih.gov/20101286/">https://pubmed.ncbi.nlm.nih.gov/20101286/</a>


Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
	Same as above	Immunocompromised (HIV or organ transplant)	--	The ICES-derived <a href="#">HIV</a> database was used to identify patients with pre-existing HIV, based on 3 physician claims in 3 years.  OHIP ICD-9: 042-044  <a href="#">CORRLINK</a> links CORR and DAD data and includes patients who received an organ transplant, and does not include dialysis patients.	<a href="https://pubmed.ncbi.nlm.nih.gov/21738786/">https://pubmed.ncbi.nlm.nih.gov/21738786/</a>
	Same as above	Dementia	The ICES-derived <a href="#">DEMENTIA</a> database was used to identify individuals with 1 hospitalization for dementia and/or 3 outpatient visits for dementia, each separated by 30 days, within 2 years, or 1 prescription from ODB.  ICD-10-CA (DAD, SDS): F00-F03, G30	OHIP ICD-9: 290, 331  <a href="#">ODB</a> 1 prescription for a cholinesterase inhibitor	<a href="https://pubmed.ncbi.nlm.nih.gov/27567819/">https://pubmed.ncbi.nlm.nih.gov/27567819/</a>

Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
	Within 1 year before January 15, 2021 (time zero)	Frailty	Identified based on the following rules, using DAD and OHIP databases: 1. Long-term care residence (i.e., admitted from/discharged to, a nursing home after hospital stay, or location of physician billing claim was long-term care facility); 2. Receipt of palliative care; 3. Two or more domains derived from frailty scales (i.e., cognitive impairment, falls, general health status, incontinence, nutrition issues, functional performance) and health services utilization (i.e., $\geq 2$ hospital stays or ED visits, geriatrician or home care visit).	--	<a href="https://pubmed.ncbi.nlm.nih.gov/28974280/">https://pubmed.ncbi.nlm.nih.gov/28974280/</a>
	Within 5 years before January 15, 2021 (time zero)	Anemia	ICD-10-CA (DAD, SDS, NACRS): D50-D53, D55, D56, D572-D574, D58-D61, D63, P55, P560, P570	OHIP ICD-9: 280-285, 773	--

Assessment	Timing	Disease, procedure or condition	CIHI-DAD, SDS or NACRS ICD-10-CA diagnosis or CCI procedure codes	OHIP ICD-9 diagnosis or fee codes; or other data source	Validation studies or documentation for some codes
	Same as above	History of transient ischemic attack or acute ischemic stroke	<p><u>Transient Ischemic Attack:</u> At least 1 hospitalization or ED visit with 1 of the following diagnosis codes:</p> <p>ICD-10-CA (DAD, NACRS): G450-G453, G458, G459, H340</p> <p><u>Acute Ischemic Stroke:</u> 1 hospitalization with a main diagnosis coded with one of the following codes:</p> <p>ICD-10-CA (DAD): I63 (except I636), I64, H341</p>	--	<a href="http://canadiansrokenetwork.ca/en/wp-content/uploads/2014/08/Stroke_Core_ENG.pdf">http://canadiansrokenetwork.ca/en/wp-content/uploads/2014/08/Stroke_Core_ENG.pdf</a>

ASTHMA: Ontario Asthma dataset; CCI: Canadian Classification of Interventions; CHF: Ontario Congestive Heart Failure dataset; CIHI: Canadian Institute for Health Information; CORR: Canadian Organ Replacement Registry; COVAXON: Ontario COVID-19 Vaccine Data; DAD: Discharge Abstract Database; DEMENTIA: Ontario Dementia dataset; ED: Emergency Department; HIV: Ontario HIV dataset; HYPER: Ontario Hypertension dataset; ICD-9: International Classification of Diseases, 9th Revision; ICD-10-CA: International Classification of Diseases, 10th Revision, Canada; ICU: Intensive Care Unit; LHIN: Local Health Integration Network; LOINC: Logical Observation Identifiers Names and Codes; NACRS: National Ambulatory Care Reporting System; ODB: Ontario Drug Benefit; ODD: Ontario Diabetes Dataset; OHIP: Ontario Health Insurance Plan; OLIS: Ontario Laboratories Information System; OLISC19: Ontario Laboratories Information System COVID-19 Laboratory Data; RPDB: Registered Persons Database; SDS: Same Day Surgery



**Figure S1. Study cohort creation.**

**Table S2 (Additional analysis 1). SARS-CoV-2 vaccination and associated risk of SARS-CoV-2 infection, or severe COVID-19 (hospitalization or death) – each assessed starting at least 14 days after the first vaccination. This analysis is limited to 614,455 individuals who had SARS-CoV-2 PCR testing during the follow-up period, from January 15, 2021 onward.**

Study outcome	Exposure state <sup>a</sup>	No. person-days of follow-up <sup>a</sup>	No. with outcome (rate per 10,000 person-days)	Unadjusted hazard ratio (95% CI%)	Adjusted hazard ratio (95% CI%) <sup>b</sup>
SARS-CoV-2 infection	Unvaccinated (N = 609,129)	67,185,613	51,187 (7.62)	1.00 (referent)	1.00 (referent)
	Vaccinated (N = 439,058)	27,220,438	4995 (1.84)	0.25 (0.25 to 0.26)	0.28 (0.27 to 0.29)
Severe COVID-19	Unvaccinated (N = 609,129)	71,414,615	2890 (0.40)	1.00 (referent)	1.00 (referent)
	Vaccinated (N = 439,058)	27,470,663	491 (0.18)	0.50 (0.46 to 0.56)	0.22 (0.20 to 0.25)

<sup>a</sup>Exposure is time-varying, therefore, some individuals may have contributed time as unvaccinated, and then subsequently, as vaccinated.

<sup>b</sup>Adjusted for age, sex, rural residence, area income quintile – each at baseline -- as well as prior diabetes mellitus, malignancy, heart failure, cardiac ischemia or arrhythmia, chronic kidney disease or venous thromboembolism.

**Table S3. SARS-CoV-2 vaccination and associated risk of SARS-CoV-2 infection, or severe COVID-19 (hospitalization or death), stratified by O and non-O blood groups, among the entire cohort.** Data are presented by time-varying exposure after first vaccination type vs. unvaccinated, with study outcomes assessed starting at least 14 days after the first vaccination.

Study outcome	Stratified by blood group	Exposure state <sup>a</sup>	No. person-days of follow-up <sup>a</sup>	No. with outcome (rate per 10,000 person-days)	Adjusted hazard ratio (95% CI) <sup>b</sup>
SARS-CoV-2 infection	Non-O	Unvaccinated (N = 1,401,213)	172,490,490	30,685 (1.78)	1.00 (referent)
		Adenovirus-vectored (N = 80,411)	4,637,314	260 (0.56)	0.49 (0.43 to 0.55)
		Modified RNA (N = 912,274)	48,108,108	2717 (0.56)	0.46 (0.44 to 0.48)
	O	Unvaccinated (N = 1,063,785)	130,718,702	20,502 (1.57)	1.00 (referent)
		Adenovirus-vectored (N = 62,947)	3,626,421	174 (0.48)	0.49 (0.42 to 0.57)
		Modified RNA (N = 688,250)	36,951,138	1844 (0.50)	0.46 (0.44 to 0.48)
Severe COVID-19	Non-O	Unvaccinated (N = 1,401,213)	175,034,046	1677 (0.10)	1.00 (referent)
		Adenovirus-vectored (N = 80,411)	4,649,419	15 (0.03)	0.27 (0.16 to 0.45)
		Modified RNA (N = 912,274)	48,242,495	296 (0.06)	0.31 (0.27 to 0.36)
	O	Unvaccinated (N = 1,063,785)	132,404,148	1213 (0.09)	1.00 (referent)
		Adenovirus-vectored (N = 62,947)	3,634,743	12 (0.03)	0.33 (0.18 to 0.58)
		Modified RNA (N = 688,250)	37,046,550	168 (0.05)	0.27 (0.22 to 0.32)

<sup>a</sup>Exposure is time-varying, therefore, some individuals may have contributed time as unvaccinated, and then subsequently, as vaccinated.

<sup>b</sup>Adjusted for age, sex, rural residence, area income quintile – each at baseline -- as well as prior diabetes mellitus, malignancy, heart failure, cardiac ischemia or arrhythmia, chronic kidney disease or venous thromboembolism.